Researchers have developed the world’s first congenital pituitary hypoplasia (CPH) model using patient-derived iPS cells. The research group succeeded in using the model to illuminate the mechanisms underlying CPH. The team has been attempting to apply this model to other pituitary diseases and drug discovery.